The Quality by Design (QbD) approach in the pharma industry was introduced more than 10 years ago. Nevertheless, this approach has not yet been fully implemented in the Pharma industry.
The Biotech field seems more prone to taking this approach, applying it during the development phase due to the fact that, especially in upstream, the number of variables and their criticality for the quality of the final product are multiple and sometimes difficult to control.